Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Cassiopea SpA    SKIN   IT0005108359

CASSIOPEA SPA (SKIN)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
07/09/2018 07/10/2018 07/11/2018 07/12/2018 07/13/2018 Date
30.2(c) 53(c) 56(c) 55.4(c) 56.4(c) Last
16 106 232 593 82 848 68 272 92 662 Volume
-7.08% +75.50% +5.66% -1.07% +1.81% Change
More quotes
Financials (EUR)
Sales 2018 -
EBIT 2018 -13,1 M
Net income 2018 -
Finance 2018 59,5 M
Yield 2018 -
Sales 2019 40,0 M
EBIT 2019 -23,2 M
Net income 2019 -
Finance 2019 23,8 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 0
EV / Sales2019 11,5x
Capitalization 482 M
More Financials
Company
Cassiopea SpA is a clinical-stage specialty pharmaceutical company.It engages in developing and commercializing and medical dermatology products focusing on the topical treatment of acne, androgenic alopecia, and genital warts.The company products include Winlevi, Breezula, CB-06-02 and... 
More about the company
Latest news on CASSIOPEA SPA
07/13CASSIOPEA SPA : half-yearly earnings release
07/10Cassiopea Announces Very Positive Top-Line Phase 3 Results for Winlevi® (Clas..
TE
07/10CASSIOPEA : Announces Very Positive Top-Line Phase 3 Results for Winlevi® (Clasc..
AQ
04/05Results of the ordinary and extraordinary shareholders meeting 2018
TE
04/05CASSIOPEA : Results of the ordinary and extraordinary shareholders meeting 2018
AQ
03/26Lists of candidates for the board of directors at the AGM 2018
TE
03/26CASSIOPEA : Lists of candidates for the board of directors at the AGM 2018
AQ
02/28Cassiopea reports on financial year 2017 and the development of its clinical ..
TE
02/28CASSIOPEA : reports on financial year 2017 and the development of its clinical p..
AQ
02/21CASSIOPEA : TIM offices searched on Cassiopea project (3)
AQ
More news
Sector news : Bio Therapeutic Drugs
07/09LONZA : restates 2017 figures after changing accounting standard
RE
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
06/29European stocks shrug off trade worries with quarterly gain
RE
06/29GILEAD SCIENCES : Rival Novartis, Gilead CAR-T therapies win European panel reco..
RE
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
02/21#ANSA | TIM offices searched on Cassiopea projec (3) - Anti-trust weighing po.. 
2017Cassiopea announces completion of recruitment of Phase II dose ranging trial .. 
2017Wake up! The team pulsed water at the Cassiopea jellyfish to disturb their 's..
1
2017Jellyfish Cassiopea that lacks a brain needs to sleep too, say scientists
2
2017Cassiopea announces results for first half of 2017  
More tweets
Qtime:36
Chart CASSIOPEA SPA
Duration : Period :
Cassiopea SpA Technical Analysis Chart | SKIN | IT0005108359 | 4-Traders
Technical analysis trends CASSIOPEA SPA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 41,6 €
Spread / Average Target -12%
Managers
NameTitle
Diana Harbort Chief Executive Officer & Executive Director
Jan Egbert de Vries Non-Executive Chairman
Marco Pasero Chief Operating Officer
Hans Christoph Tanner CFO, Head-Investor & Media Relations
Luigi Moro Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
CASSIOPEA SPA62.07%563
GILEAD SCIENCES8.01%100 614
VERTEX PHARMACEUTICALS20.45%45 997
REGENERON PHARMACEUTICALS-2.53%38 951
GENMAB5.49%10 457
NEUROCRINE BIOSCIENCES, INC.32.48%9 250